Newsroom

Sorted by: Latest
-

Cresce a adesão ao Miro MCP à medida que usuários adotam a tela para colaboração com IA

SAN FRANCISCO e AMSTERDAM--(BUSINESS WIRE)--Miro®, camada de colaboração e contexto para a era da IA, registrou mais de 16 milhões de chamadas para seu servidor MCP desde o lançamento em fevereiro de 2026, com o volume de uso mais do que dobrando desde maio. Somente em setembro, as chamadas via MCP caminham para atingir a marca de 6 milhões*. As equipes dependem cada vez mais da IA ​​para acelerar o trabalho — desde a descoberta e o planejamento até o design e a programação. No entanto, a maior...
-

Miro MCP a le vent en poupe, les utilisateurs s'appropriant son canevas pour la collaboration en IA

SAN FRANCISCO et AMSTERDAM--(BUSINESS WIRE)--Miro®, la couche de collaboration et de contexte de l’ère de l’IA, a enregistré plus de 16 millions d’appels vers son serveur MCP depuis son lancement en février 2026, l’utilisation ayant plus que doublé depuis mai. Rien qu'en septembre, MCP est en bonne voie pour atteindre les six millions d'appels*. Les équipes s’appuient de plus en plus sur l’IA pour accélérer le travail, de la découverte et de la planification à la conception et au code. Pourtant...
-

Miro MCP auf Wachstumskurs: Immer mehr Nutzer setzen bei der KI-Zusammenarbeit auf die gemeinsame Arbeitsfläche

SAN FRANCISCO und AMSTERDAM--(BUSINESS WIRE)--Miro®, die Kollaborations- und Kontextplattform für das KI-Zeitalter, verzeichnet mehr als 16 Millionen Aufrufe seines MCP-Servers seit der Einführung im Februar 2026. Seit Mai hat sich die Nutzung mehr als verdoppelt. Allein im September dürfte die Zahl der MCP-Aufrufe 6 Millionen* erreichen. Teams setzen zunehmend auf KI, um ihre Arbeit zu beschleunigen – von Recherche und Planung bis hin zu Design und Programmierung. Die meisten Interaktionen mit...
-

Miro MCP gana impulso mientras los usuarios adoptan el lienzo para colaborar con IA

SAN FRANCISCO y ÁMSTERDAM--(BUSINESS WIRE)--Miro®, la plataforma de colaboración y contexto para la era de la IA, ha registrado más de 16 millones de solicitudes a su servidor MCP desde que fuera lanzado en febrero de 2026, y su uso se ha duplicado con creces desde mayo. Solo en septiembre, las solicitudes a MCP van camino de sumar 6 millones en total*. Los equipos recurren cada vez más a la IA para acelerar las tareas, desde el descubrimiento y la planificación, hasta el diseño y la programaci...
-

CIO Launches SmartCoby Ultra Slim SS5K on Kickstarter, Building on Ultra Slim 3K's Breakout Crowdfunding Success

OSAKA, Japan--(BUSINESS WIRE)--CIO, a Japan based charging accessories brand, has launched its Kickstarter campaign for SmartCoby Ultra Slim SS5K, a 5,000mAh wireless power bank in a 6.83mm stainless steel body. The campaign is live now on Kickstarter, with Super Early Bird pledges starting at $45.74. SmartCoby Ultra Slim SS5K pairs a semi-solid battery cell with a stainless steel shell, making it one of the thinnest 5,000mAh wireless power banks in its category. It is built with NovaCore C3, a...
-

VDURA Data Platform V12 Now Generally Available, the Hyperscaler Storage Playbook to AI Factories and Neoclouds on Supermicro

PITTSBURGH & ABU DHABI, United Arab Emirates--(BUSINESS WIRE)--VDURA, provider of high-performance data storage infrastructure for AI factories and neoclouds, today announced the general availability of the VDURA® Data Platform V12, the release that turns the platform into a multi-tenant, API-driven storage service for GPU clouds and AI factories. V12 ships as a qualified solution on Supermicro Building Block Solutions®, scaling from 8 to 100,000 GPUs on one software stack. VDURA will showcase...
-

Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FDA accepts filing for fenebrutinib, an investigational BTK inhibitor, for relapsing (RMS) and primary progressive (PPMS) multiple sclerosis....
-

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zasocitinib’s supe...
-

EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and effi...
-

Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026

VIENNA--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, today announced its scientific programme at the 35th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Vienna from 30 September to 3 October 2026. As Gold Sponsor of this year’s congress, Almirall will present more than 20 abstracts on clinical and real-world evidence spanning atopic dermatitis (AD), psoriasis (PsO) and actinic keratosis (AK), and a...